About Us - ADHD testing with Qbtech

Technology to enable outcome focused ADHD care

For the longest time, managing attention deficit hyperactive disorder relied solely on subjective information. The process was complex and time-consuming. There was a need for change – and Qbtech was born.

As leaders in ADHD technology, we believe that everyone, everywhere must have access to reliable and effective care. Our technology-driven approach combines objective solutions with subjective data and helps clinicians like you achieve positive outcomes for your patients.

2002

The Gillberg family join forces with leading psychologist Fredrik Ulberstad and launch Qbtech.

2004

QbTest gets FDA clearance (K040894) for use in ADHD evaluation.

2014

QbTest is FDA cleared (K133382) for treatment evaluation and monitoring for ages 6-60.

2018

QbTest featured in randomized control trial – AQUA study is published showing QbTest as a tool that can help reduce the time to diagnosis and help cut costs through efficiency savings.

2020

Qbtech releases remote testing (telehealth) powered by QbCheck in response to the Covid-19 pandemic.

2022

Qbtech and the AHSN Network win ‘Best Mental Health Partnership with the NHS’.

2022

Received UK mental health and wellbeing’s ‘Most Innovative Mental Health Innovation’ award.

2023

National Institute for Clinical Excellence (NICE) appraises QbTest.

2023

Successful completion of the Focus ADHD national program in the UK (started in 2019).

2024

First QbTest clinic established under the NHS Scotland Health board.

2024

1 million patients supported with Qbtech tests.

2003

The team in Gotenburg built our first objective ADHD test – QbTest.

2012

QbTest FDA cleared (K122149) for use in adolescent and adult evaluation (evaluation only).

2016

QbCheck is launched – the world's first online, FDA cleared, ADHD test (K143468: similar indications as QbTest).

2020

QbTest is announced as one of 11 innovations selected to join NHS Innovation Accelerator (NIA).

2020

QbTest is included in Focus ADHD – a National Programme from the innovation arm of NHS England, the Academic Health Science Network (AHSN). The programme has resulted in 70% of child clinics in England including QbTest.

2022

Qbtech partners with Verdane to accelerate growth in ADHD diagnostics software market.

2022

The ADHD Expert Consortium was founded.

2023

Receive the ‘Innovate Awards – Innovation Spread with the AHSN Network’.

2023

QbCheck is integrated into the CHIRP pathway in New Zealand.

2024

QbTest is the first and only medical technology to be recommended in NICE's diagnostic guidelines for assessing ADHD in children and young people.

Workplace and culture

At Qbtech, we're more than just an organisation – we're a community where ideas are nurtured and innovation thrives.

We’re driven by a profound commitment to reshape the ADHD landscape. At the core of our company is our dedication to becoming a collaborative platform for patients and clinicians alike.

Above all things we value openness, innovation, and professionalism. Being a people-oriented company, we strongly believe in creating an environment that sparks curiosity, creativity, and passion. We value and respect work-life balance and work towards recognising success, exhibiting fairness, and maintaining a positive organisational culture.

What’s the culture at Qbtech like?

We love our fikas! The fika (pronounced “fee-kah”) is a very important Swedish tradition of gathering with friends and family over coffee (or tea) and connecting. Fikas give us the opportunity to hang out, get to know one another, and have meaningful discussions about personal and professional achievements.

We're a dynamic and fast-paced setting where challenges are viewed as opportunities for learning and growth. Every Qbtech team member is devoted to helping others and works with a common goal of improving the lives of people with ADHD.